Medical Oncology

, Volume 27, Supplement 1, pp 53–61 | Cite as

Treatment options for multiple myeloma patients with high-risk disease

  • Sikander Ailawadhi
  • Aisha Masood
  • Taimur Sher
  • Kena C. Miller
  • Margaret Wood
  • Kelvin Lee
  • Asher Chanan-KhanEmail author
Original Paper


Multiple myeloma is a heterogeneous malignant disorder with a variable clinical course suggestive of diverse biological factors that have important prognostic implications. Despite development of several new therapeutic agents and substantially effective novel combination regimens, myeloma remains an incurable disease. There is an emphasis to define new biologic parameters to accurately identify patients with aggressive disease biology. This will allow more informed treatment decisions based on the biology of the disease, resulting in further optimization of management strategies in specific patient subgroups. Among biological parameters of risk stratification, cytogenetics has emerged as arguably the most important dependable and clinically convenient. These are being increasingly utilized to develop therapeutic stratification in newer clinical trials. Appraisal of current data suggests that patients with high-risk cytogenetics have a worse prognosis. However, treatment with novel agents has changed this variable. There is emerging evidence that patients with aggressive disease biology are fairing better with innovative treatment regimens utilizing a combination of conventional and novel agents. This review focuses on current and emerging data about defining high-risk disease in multiple myeloma and the various therapeutic options for this group of patients.


Multiple myeloma Cytogenetics High-risk FISH 


Conflict of interest statements

Sikander Ailawadhi: Speaker’s Bureau—Celgene, Millennium, Ortho BioTech; Advisory board—Millennium; Aisha Masood: No disclosures to report; Taimur Sher: Advisory board for Millennium; Kena C. Miller: Speakers bureau for Celgene, Millennium, Cephalon, Medtonic/Kyphon; Advisory Board for Celgene and Millennium; Margaret Wood: No disclosures to report; Kelvin Lee: No disclosures to report; Asher Chanan-Khan: Speakers bureau—Celgene, Millennium; Advisory board—Celgene, Millennium. All authors received an honorarium for their participation in this supplement.


  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.CrossRefPubMedGoogle Scholar
  2. 2.
    Barlogie B, Epstein J, Selvanayagam P, Alexanian R. Plasma cell myeloma—new biological insights and advances in therapy. Blood. 1989;73:865–79.PubMedGoogle Scholar
  3. 3.
    Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33.CrossRefPubMedGoogle Scholar
  4. 4.
    Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–54.CrossRefPubMedGoogle Scholar
  5. 5.
    Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20.CrossRefPubMedGoogle Scholar
  6. 6.
    Bladé JF-LP, Bosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158:1889–93.CrossRefPubMedGoogle Scholar
  7. 7.
    Winearls CG. Acute myeloma kidney. Kidney Int. 1995;48:1347–61.CrossRefPubMedGoogle Scholar
  8. 8.
    Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007;109:2604–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Simonsson B, Brenning G, Kallander C, Ahre A. Prognostic value of serum lactic dehydrogenase (s-ldh) in multiple myeloma. Eur J Clin Invest. 1987;17:336–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Brown RD, Snowdon L, Uhr E, Gibson J, Joshua D. C-reactive protein (crp) levels do not reflect disease status in patients with multiple myeloma. Leuk Lymphoma. 1993;9:509–12.CrossRefPubMedGoogle Scholar
  11. 11.
    Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111:785–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Snozek CL, Katzmann JA, Kyle RA, Dispenzieri A, Larson DR, Therneau TM, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia. 2008;22:1933–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Rawstron AC, Davies FE, DasGupta R, Ashcroft AJ, Patmore R, Drayson MT, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood. 2002;100:3095–100.CrossRefPubMedGoogle Scholar
  14. 14.
    Mateo G, Montalban MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutierrez N, et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the pethema/gem cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol. 2008;26:2737–44.CrossRefPubMedGoogle Scholar
  15. 15.
    Lokhorst HM, Boom SE, Bast BJ, Ballieux RE. Determination of the plasma cell labelling index with bromodeoxyuridine in a double fluorescence technique. Br J Haematol. 1986;64:271–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Steensma DP, Gertz MA, Greipp PR, Kyle RA, Lacy MQ, Lust JA, et al. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. Blood. 2001;97:2522–3.CrossRefPubMedGoogle Scholar
  17. 17.
    Greipp PR, Lust JA, O’Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81:3382–7.PubMedGoogle Scholar
  18. 18.
    Vela-Ojeda J, Garcia-Ruiz Esparza MA, Padilla-Gonzalez Y, Sanchez-Cortes E, Garcia-Chavez J, Montiel-Cervantes L, et al. Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor. Ann Hematol. 2009;88:59–66.CrossRefPubMedGoogle Scholar
  19. 19.
    Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD Jr, et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. 2007;25:1121–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the intergroup francophone du myelome. Blood. 2007;109:3489–95.CrossRefPubMedGoogle Scholar
  21. 21.
    Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101:4569–75.CrossRefPubMedGoogle Scholar
  22. 22.
    Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2:175–87.CrossRefPubMedGoogle Scholar
  23. 23.
    Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F, et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with total therapy i: interpretation in the context of global gene expression. Blood. 2003;101:3849–56.CrossRefPubMedGoogle Scholar
  24. 24.
    Shaughnessy J, Tian E, Sawyer J, Bumm K, Landes R, Badros A, et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase fish. Blood. 2000;96:1505–11.PubMedGoogle Scholar
  25. 25.
    Shaughnessy J Jr, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy ii. Br J Haematol. 2003;120:44–52.CrossRefPubMedGoogle Scholar
  26. 26.
    Zojer N, Konigsberg R, Ackermann J, Fritz E, Dallinger S, Kromer E, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood. 2000;95:1925–30.PubMedGoogle Scholar
  27. 27.
    Kaufmann H, Kromer E, Nosslinger T, Weltermann A, Ackermann J, Reisner R, et al. Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase fish only are prognostically relevant in multiple myeloma. Eur J Haematol. 2003;71:179–83.CrossRefPubMedGoogle Scholar
  28. 28.
    Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood. 1995;86:4250–6.PubMedGoogle Scholar
  29. 29.
    Wu KL, Beverloo B, Lokhorst HM, Segeren CM, van der Holt B, Steijaert MM, et al. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Br J Haematol. 2007;136:615–23.CrossRefPubMedGoogle Scholar
  30. 30.
    Fonseca R, Debes-Marun CS, Picken EB, Dewald GW, Bryant SC, Winkler JM, et al. The recurrent igh translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003;102:2562–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Smadja NV, Leroux D, Soulier J, Dumont S, Arnould C, Taviaux S, et al. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer. 2003;38:234–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Gutierrez NC, Garcia JL, Hernandez JM, Lumbreras E, Castellanos M, Rasillo A, et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood. 2004;104:2661–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P, et al. The level of taci gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood. 2005;106:1021–30.CrossRefPubMedGoogle Scholar
  34. 34.
    Pellat-Deceunynck C. Tumour-associated antigens in multiple myeloma. Br J Haematol. 2003;120:3–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007;109:1692–700.CrossRefPubMedGoogle Scholar
  36. 36.
    Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Zhan F, Barlogie B, Mulligan G, Shaughnessy JD Jr, Bryant B. High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. Blood. 2008;111:968–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Decaux O, Lode L, Magrangeas F, Charbonnel C, Gouraud W, Jezequel P, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the intergroupe francophone du myelome. J Clin Oncol. 2008;26:4798–805.CrossRefPubMedGoogle Scholar
  39. 39.
    Dring AM, Davies FE, Fenton JA, Roddam PL, Scott K, Gonzalez D, et al. A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma. Clin Cancer Res. 2004;10:5692–701.CrossRefPubMedGoogle Scholar
  40. 40.
    Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007;21:529–34.CrossRefPubMedGoogle Scholar
  41. 41.
    Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007;21:151–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–17.CrossRefPubMedGoogle Scholar
  43. 43.
    Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–98.CrossRefPubMedGoogle Scholar
  44. 44.
    San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–17.CrossRefPubMedGoogle Scholar
  45. 45.
    Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2009;114:518–21.CrossRefPubMedGoogle Scholar
  46. 46.
    Reece D, Song KW, Fu T, Roland B, Chang H, Horsman DE, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood. 2009;114:522–5.CrossRefPubMedGoogle Scholar
  47. 47.
    Knop S, Gerecke C, Liebisch P, Topp MS, Platzbecker U, Sezer O, et al. Lenalidomide, adriamycin, and dexamethasone (rad) in patients with relapsed and refractory multiple myeloma: a report from the german myeloma study group dsmm (deutsche studiengruppe multiples myelom). Blood. 2009;113:4137–43.CrossRefPubMedGoogle Scholar
  48. 48.
    Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K, et al. Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood. 2008;112:3115–21.CrossRefPubMedGoogle Scholar
  49. 49.
    Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021–30.CrossRefPubMedGoogle Scholar
  50. 50.
    Chang H, Qi XY, Samiee S, Yi QL, Chen C, Trudel S, et al. Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplant. 2005;36:793–6.CrossRefPubMedGoogle Scholar
  51. 51.
    Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood. 2005;106:2837–40.CrossRefPubMedGoogle Scholar
  52. 52.
    Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998;92:3131–6.PubMedGoogle Scholar
  53. 53.
    Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (ifm99–03 trial) with tandem autologous stem cell transplantation (ifm99–04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107:3474–80.CrossRefPubMedGoogle Scholar
  54. 54.
    Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356:1110–20.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Sikander Ailawadhi
    • 1
  • Aisha Masood
    • 2
  • Taimur Sher
    • 3
  • Kena C. Miller
    • 3
  • Margaret Wood
    • 3
  • Kelvin Lee
    • 3
  • Asher Chanan-Khan
    • 3
    Email author
  1. 1.University of Southern CaliforniaLos AngelesUSA
  2. 2.Hackensack Medical CenterHackensackUSA
  3. 3.Roswell Park Cancer InstituteBuffaloUSA

Personalised recommendations